The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The clinical significance of MRD in AL amyloidosis
In this video, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the clinical significance of measurable residual disease (MRD) in light-chain (AL) amyloidosis. Dr Paiva notes that a multicenter international European study involving 320 patients with AL amyloidosis demonstrated the prognostic value of MRD but, unfortunately, found no association between MRD status and organ response. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Light-chain amyloidosis is a much more rare disease when compared to myeloma, but it’s also a plasma cell dyscrasia. And in contrast to myeloma, where we have a large body of evidence about the role of MRD, in AL amyloidosis it remains uncertain, but it could be important to redefine CR and eventually to associate with organ response. And because of the uncertainty and lack of data, that’s why we decided to perform a multicenter international European study that was able to evaluate the value of MRD in up to 320 patients with light-chain amyloidosis, these are unprecedented numbers, and in this study we showed that MRD is of clear prognostic value...
Light-chain amyloidosis is a much more rare disease when compared to myeloma, but it’s also a plasma cell dyscrasia. And in contrast to myeloma, where we have a large body of evidence about the role of MRD, in AL amyloidosis it remains uncertain, but it could be important to redefine CR and eventually to associate with organ response. And because of the uncertainty and lack of data, that’s why we decided to perform a multicenter international European study that was able to evaluate the value of MRD in up to 320 patients with light-chain amyloidosis, these are unprecedented numbers, and in this study we showed that MRD is of clear prognostic value. It helps redefine patients’ risk that are in the hematological CR. It also helps to redefine risk according to staging at diagnosis, mainly cardiac involvement, and its prognostic in all treatment scenarios including transplant and exposure to bortezomib and daratumumab. Unfortunately, we haven’t found an association between MRD response and organ response.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Bristol Myers Squibb/Celgene, Janssen, Sanofi, and Takeda: Consultancy; Adaptive, Amgen, Becton Dickinson, Bristol Myers Squibb/Celgene, Janssen, Merck, Novartis, Roche, Sanofi and Takeda: Honoraria; Aztra Zeneca, Bristol Myers Squibb/Celgene, EngMab, Roche, Sanofi, and Takeda: Research Funding.
